Recent Analyst Stock Rating Initiation News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Analyst Stock Ratings Initiations
| Buy Now | Get Alert | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 07/26/2024 | DASH | Buy Now | DoorDash | $104.74 | 62.31% | Redburn Atlantic | James Cordwell53% | → $170 | Initiates | → Buy | Get Alert |
| 07/26/2024 | ASRT | Buy Now | Assertio Holdings | $1.52 | 97.37% | Maxim Group | Naz Rahman32% | → $3 | Initiates | → Buy | Get Alert |
| 07/26/2024 | DAVE | Buy Now | Dave | $35.95 | 47.43% | Lake Street | Jacob Stephan35% | → $53 | Initiates | → Buy | Get Alert |
| 07/26/2024 | BDSX | Buy Now | Biodesix | $1.80 | 66.67% | Craig-Hallum | Bill Bonello59% | → $3 | Initiates | → Buy | Get Alert |
| 07/26/2024 | MITT | Buy Now | AG Mortgage IT | $7.74 | 16.28% | Piper Sandler | Brad Capuzzi76% | → $9 | Initiates | → Overweight | Get Alert |
| 07/26/2024 | CRVO | Buy Now | CervoMed | $14.03 | 149.47% | Morgan Stanley | Jeffrey Hung58% | → $35 | Initiates | → Overweight | Get Alert |
| 07/26/2024 | RIOT | Buy Now | Riot Platforms | $11.21 | 60.57% | Stifel | Bill Papanastasiou78% | → $18 | Initiates | → Speculative Buy | Get Alert |
| 07/26/2024 | DNTH | Buy Now | Dianthus Therapeutics | $28.97 | 100.21% | Baird | Joel Beatty71% | → $58 | Initiates | → Outperform | Get Alert |
| 07/25/2024 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.51 | 99.45% | Citigroup | David Hoang61% | → $7 | Initiates | → Buy | Get Alert |
| 07/25/2024 | IDXX | Buy Now | IDEXX Laboratories | $469.71 | 23.48% | BTIG | Mark Massaro61% | → $580 | Initiates | → Buy | Get Alert |
| 07/25/2024 | BNAI | Buy Now | Brand Engagement Network | $2.60 | 130.77% | Maxim Group | Jack Vander Aarde28% | → $6 | Initiates | → Buy | Get Alert |
| 07/25/2024 | PFMT | Buy Now | Performant Finl | $3.58 | 123.46% | B. Riley Securities | Kyle Bauser67% | → $8 | Initiates | → Buy | Get Alert |
| 07/25/2024 | OBIO | Buy Now | Orchestra BioMed Hldgs | $8.60 | 74.42% | B. Riley Securities | Kyle Bauser67% | → $15 | Initiates | → Buy | Get Alert |
| 07/25/2024 | SPRY | Buy Now | ARS Pharmaceuticals | $10.98 | 63.93% | Raymond James | Ryan Deschner34% | → $18 | Initiates | → Outperform | Get Alert |
| 07/25/2024 | CBRE | Buy Now | CBRE Group | $110.55 | -5.02% | Morgan Stanley | Ronald Kamdem67% | → $105 | Initiates | → Equal-Weight | Get Alert |
| 07/25/2024 | MGNI | Buy Now | Magnite | $14.39 | 45.93% | Lake Street | Eric Martinuzzi47% | → $21 | Initiates | → Buy | Get Alert |
| 07/25/2024 | FTK | Buy Now | Flotek Industries | $4.59 | 41.61% | Roth MKM | Gerry Sweeney65% | → $6.5 | Initiates | → Buy | Get Alert |
| 07/25/2024 | NARI | Buy Now | Inari Medical | $53.83 | — | William Blair | Margaret Andrew16% | — | Initiates | → Outperform | Get Alert |
| 07/25/2024 | ZTS | Buy Now | Zoetis | $179.84 | 22.33% | BTIG | Mark Massaro61% | → $220 | Initiates | → Buy | Get Alert |
| 07/25/2024 | CATX | Buy Now | Perspective Therapeutics | $13.70 | 75.18% | B of A Securities | Alec Stranahan42% | → $24 | Initiates | → Buy | Get Alert |
| 07/25/2024 | AURA | Buy Now | Aura Biosciences | $10.36 | 102.7% | HC Wainwright & Co. | Edward White50% | → $21 | Initiates | → Buy | Get Alert |
| 07/25/2024 | LB | Buy Now | LandBridge | $30.13 | 19.48% | Janney Montgomery Scott | Sean Milligan39% | → $36 | Initiates | → Buy | Get Alert |
| 07/25/2024 | UTI | Buy Now | Universal Technical | $19.43 | 13.23% | Truist Securities | Jasper Bibb70% | → $22 | Initiates | → Buy | Get Alert |
| 07/25/2024 | QBTS | Buy Now | D-Wave Quantum | $0.99 | 203% | B. Riley Securities | Craig Ellis83% | → $3 | Initiates | → Buy | Get Alert |
| 07/25/2024 | RGTI | Buy Now | Rigetti Computing | $1.07 | 180.37% | B. Riley Securities | Craig Ellis83% | → $3 | Initiates | → Buy | Get Alert |
About Luke Jacobi
Luke Jacobi is a distinguished professional known for his role as President at Benzinga, a renowned financial media outlet. With a background in business operations and management, Luke brings valuable expertise to his position, overseeing various aspects of Benzinga’s operations. His contributions play a crucial role in the company’s success, ensuring efficiency and effectiveness across different departments. Prior to his role at Benzinga, Luke has held positions that have honed his skills in leadership and strategic decision-making. With a keen understanding of the financial industry and a commitment to driving innovation, Luke continues to make significant contributions to Benzinga’s mission of providing high-quality financial news and analysis.